Applied Therapeutics, Inc.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Their lead product candidate, AT-007, has completed phase 1/2 trials for galactosemia treatment in healthy volunteers and adults, with ongoing pediatric clinical studies. Additionally, the company is developing AT-001, currently in phase III trials for treating diabetic cardiomyopathy and peripheral neuropathy. Their preclinical stage products include AT-003 for diabetic retinopathy and AT-104, a PI3K inhibitor for orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.

Products

• AT-007 for galactosemia treatment

• AT-001 for diabetic cardiomyopathy and peripheral neuropathy

• AT-003 for diabetic retinopathy

• AT-104, a PI3K inhibitor for T Cell Acute Lymphoblastic Leukemia